Lipoprotein apheresis: an update

References

• de Gennes JL, Touraine R, Maunand B et al. [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis as heroic treatment.] Bull. Mem. Soc. Med. Hop. Paris 118, 1377–1402 (1967).
   Google Scholar
• Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif. Organs 27(12), 1116–1122 (2003).
   Google Scholar
• Richter WO, Jacob BG, Ritter MM, Suhler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42(7), 888–894 (1993).
   Google Scholar
• Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration – safe and effective methodology to perform lipid-apheresis. Transfus. Apher. Sci. 30(3), 245–254 (2004).
   Google Scholar
• Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R, Geiss HC. Dextran-sulfateadsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis – comparison of performance characteristics with DALI and Lipidfiltration. J. Clin. Apher. 22(4), 215–223 (2007).
   Google Scholar
• Seidel D. HELP apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artif. Organs 20(4), 303–310 (1996).
   Google Scholar
• Armstrong VW, Schuff-Werner P, Eisenhauer T, Helmhold M, Stix M, Seidel D. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. Chem. Phys. Lipids 67–68, 315–321 (1994).
   Google Scholar
• Drager LJ, Julius U, Kraenzle K et al. DALI – the first human whole-blood low-density lipoprotein and lipoprotein(a) apheresis system in clinical use: procedure and clinical results. Eur. J. Clin. Invest. 28(12), 994–1002 (1998).
   Google Scholar
• Julius U, Frind A, Tselmin S, Kopprasch S, Poberschin I, Siegert G. Comparison of different LDL apheresis methods. Expert Rev. Cardiovasc. Ther. 6(5), 629–639 (2008).
   Google Scholar
• Julius U, Tselmin S, Fischer S, Passauer J, Bornstein SR. The Dresden Apheresis Center – experience with LDL apheresis and immunoadsorption. Atheroscler. Suppl. 10(5), 12–16 (2009).▪▪ Tells the story of the Apheresis Center at the University Hospital Dresden.
   Google Scholar
• Schettler V, Neumann CL, Hulpke-Wette M, Hagenah GC, Schulz EG, Wieland E. Current view: indications for extracorporeal lipid apheresis treatment. Clin. Res. Cardiol. Suppl. 7(Suppl. 1), 15–19 (2012).
   Google Scholar
• Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the national lipid association expert panel on familial hypercholesterolemia. J. Manag. Care Pharm. 19(2), 139–149 (2013).
   Google Scholar
• Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 198(2), 247–255 (2008).
   Google Scholar
• Stefanutti C, Morozzi C, Perrone G, Di GS, Vivenzio A, D’Alessandri G. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating. G. Chir. 33(11–12), 444–449 (2012).
   Google Scholar
• Julius U, Taseva K, Fischer S, Passauer J, Bornstein SR. Current situation of lipoprotein apheresis in Saxony. Atheroscler. Suppl. 14(1), 51–55 (2013).▪▪ Describes the situation with lipoprotein apheresis in a federal state of Germany for the first time.
   Google Scholar
• Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz E. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon. Outcomes Res. 5, 189–192 (2013).
   Google Scholar
• Bundesministerium für Gesundheit und Soziale Sicherung. Bekanntmachung des Bundesausschusses der Ärzte und Krankenkassen über eine Änderung der Richtlinien über die Bewertung ärztlicher Untersuchungs- und Behandlungsmethoden gemäß § 135 Abs. 1 des Fünften Buches Sozialgesetzbuch (SGB V) (BUB-Richtlinien) vom 24. März 2003. BAnz. 123, 14 486 (2003).
   Google Scholar
• Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3–46 (2011).▪▪ Important international guidelines for the diagnostics and treatment of lipid disorders.
   Google Scholar
• Taseva K, Fischer S, Passauer J, Weiss N, Bornstein SR, Julius U. Factors inducing cardiovascular events in patients treated by lipoprotein apheresis. Atheroscler. Suppl. 14(1), 45–50 (2013).
   Google Scholar
• Bundesministerium für Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung. Vom 19. Juni 2008. BAnz. 138, 3321 (2008).
   Google Scholar
• Weiss N. A critical review on the use of lipid apheresis and rheophoresis for treatment of peripheral arterial disease and the diabetic foot syndrome. Semin. Dial. 25, 220–227 (2012).
   Google Scholar
• Medical Advisory Secretariat. Low density lipoprotein apheresis: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 7(5), 1–101 (2007).
   Google Scholar
• Safarova MS, Ezhov MV, Afanasieva OI et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl. 14(1), 93–99 (2013).▪▪ Reports on the effects of a specific lipoprotein(a) apheresis on coronary arteries.
   Google Scholar
• Stefanutti C, Di GS, Mazzarella B, Castelli A. LDL apheresis: a novel technique (LIPOCOLLECT 200). Artif. Organs 33(12), 1103–1108 (2009).
   Google Scholar
• Sanchez AP, Cunard R, Ward DM. The selective therapeutic apheresis procedures. J. Clin. Apheresis 28, 20–29 (2013).
   Google Scholar
• Julius U, Fischer S, Schatz U, Passauer J, Bornstein S. Why an apheresis center should offer more than one lipoprotein apheresis method. Ther. Apher. Dial. 17(2), 179–184 (2013).▪▪ Summarizes the Dresden experience in patients treated with several lipoprotein apheresis methods.
   Google Scholar
• Schettler V, Neumann CL, Hagenah GC, Schulz EG, Wieland E. How to optimize lipoprotein apheresis treatment – a second look. Atheroscler. Suppl. 14(1), 89–92 (2013).
   Google Scholar
• Moriarty PM, Luyendyk JP, Gibson CA, Backes JM. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4. Am. J. Cardiol. 105(11), 1585–1587 (2010).
   Google Scholar
• Opole IO, Belmont JM, Kumar A, Moriarty PM. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am. J. Cardiol. 100(9),1416–1418 (2007).
   Google Scholar
• Orsoni A, Saheb S, Levels JH et al. LDL-apheresis depletes apoE-HDL and prebeta1-HDL in familial hypercholesterolemia: relevance to atheroprotection. J. Lipid Res. 52(12), 2304–2313 (2011).
   Google Scholar
• Orsoni A, Villard EF, Bruckert E et al. Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia. J. Lipid Res. 53(4), 767–775 (2012).
   Google Scholar
• Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 152(2), 519–526 (2000).▪▪ Publishes a formula to calculate interval mean values of lipid concentrations in patients treated with lipoprotein apheresis.
   Google Scholar
• Borberg H. 26 years of LDL-apheresis: a review of experience. Transfus. Apher. Sci. 41(1), 49–59 (2009).
   Google Scholar
• Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler. Suppl. 14(1), 19–27 (2013).
   Google Scholar
• Donner MG, Parhofer KG, Richter WO, Schwandt P. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism 48(7), 881–886 (1999).
   Google Scholar
• Moriarty PM, Gibson CA, Kensey KR, Hogenauer W. Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. Am. J. Cardiol. 93(8), 1044–1046 (2004).
   Google Scholar
• Bosch T, Wendler T, Jaeger BR, Samtleben W. Improvement of hemorheology by DALI apheresis: acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients. Ther. Apher. 5(5), 372–376 (2001).
   Google Scholar
• Otto C, Geiss HC, Laubach E, Schwandt P. Effects of direct adsorption of lipoproteins apheresis on lipoproteins, low-density lipoprotein subtypes, and hemorheology in hypercholesterolemic patients with coronary artery disease. Ther. Apher. 6(2), 130–135 (2002).
   Google Scholar
• Moriarty PM, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158(2), 495–498 (2001).
   Google Scholar
• Otto C, Geiss HC, Empen K, Parhofer KG. Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis 174(1), 151–156 (2004).current status. Eur. Heart J. 31(23), 2844–2853 (2010).▪▪ Represents a milestone among the papers relating to the lipoprotein(a) story.
   Google Scholar
• Stefanutti C, Vivenzio A, Ferraro PM, Morozzi C, Belotherkovsky D. Apheresisinducible cytokine pattern change in severe, genetic dyslipidemias. Cytokine 56(3), 835–841 (2011).
   Google Scholar
• Stefanutti C, Morozzi C, Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine 56(3), 842–849 (2011).
   Google Scholar
• Empen K, Otto C, Brodl UC, Parhofer KG. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J. Clin. Apher. 17(1), 38–43 (2002).
   Google Scholar
• Moriarty PM, Gibson CA. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am. J. Cardiol. 95(10), 1246–1247 (2005).
   Google Scholar
• Spieker LE, Ruschitzka F, Badimon JJ, Noll G, Corti R. Shear stress-dependent platelet function after LDL cholesterol apheresis. Thromb. Res. 113(6), 395–398 (2004).
   Google Scholar
• Lamounier-Zepter V, Look C, Ehrhart-Bornstein M, Bornstein SR, Fischer S, Julius U. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels. Atheroscler. Suppl. 14(1), 129–134 (2013).
   Google Scholar
• Koziolek MJ, Mueller GA. Impact of LDL-apheresis on inflammation and microcirculation. Atheroscler. Suppl. 10(5), 56–58 (2009).
   Google Scholar
• Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W, Horstkotte D. Improved coronary vasodilatatory capacity by HELP apheresis: comparing initial and chronic treatment. Ther. Apher. Dial. 10(6), 510–517 (2006).▪▪ Effect of heparin-induced extracorporeal LDL precipitation apheresis on coronary blood flow shown in patients for the first time.
   Google Scholar
• Rossenbach J, Mueller GA, Lange K et al. Lipid-apheresis improves microcirculation of the upper limbs. J. Clin. Apher. 26(4), 167–173 (2011).
   Google Scholar
• Reimann M, Julius U, Haink K et al. LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis 213(1), 212–217 (2010).
   Google Scholar
• Reimann M, Prieur S, Lippold B et al. Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atheroscler. Suppl. 10(5), 39–43 (2009).
   Google Scholar
• Terai N, Julius U, Haustein M, Spoerl E, Pillunat LE. The effect of low-density lipoprotein apheresis on ocular microcirculation in patients with hypercholesterolaemia: a pilot study. Br. J. Ophthalmol. 95(3), 401–404 (2011).
   Google Scholar
• van Buuren F, Kreickmann S, Horstkotte D, Kottmann T, Mellwig KP. HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures. Clin. Res. Cardiol. Suppl. 7(Suppl. 1), 24–30 (2012).
   Google Scholar
• Koziolek MJ, Hennig U, Zapf A et al. Retrospective analysis of long-term lipid apheresis at a single center. Ther. Apher. Dial. 14(2), 143–152 (2010).
   Google Scholar
• Lappegard KT, Hovland A. Side effects in LDL apheresis: types, frequency and clinical relevance. Clin. Lipidol. 6(6), 717–722 (2011).
   Google Scholar
• Dihazi H, Koziolek MJ, Sollner T et al. Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol. Dial. Transplant. 23(9), 2925–2935 (2008).
   Google Scholar
• Bramlage CP, Armstrong VW, Zapf A, Bramlage P, Mueller GA, Koziolek MJ. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. Ther. Apher. Dial. 14(2), 136–142 (2010).
   Google Scholar
• Schuff-Werner P, Gohlke H, Bartmann U et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extracorporeal LDL-precipitation. Eur. J. Clin. Invest. 24(11), 724–732 (1994).
   Google Scholar
• Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82(12), 1489–1495 (1998).
   Google Scholar
• Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93(10), 1826–1835 (1996).
   Google Scholar
• Kroon AA, van Asten WN, Stalenhoef AF. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann. Intern. Med. 125(12), 945–954 (1996).
   Google Scholar
• Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler. Suppl. 14(1), 67–70 (2013).
   Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor:
   Google Scholar
• Berthold HK, Gouni-Berthold I. Hyperlipoproteinemia(a): clinical significance and treatment options. Atheroscler. Suppl. 14(1), 1–5 (2013).
   Google Scholar
• Bennet A, Di AE, Erqou S et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Intern. Med. 168(6), 598–608 (2008).
   Google Scholar
• Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302(4), 412–423 (2009).
   Google Scholar
• Erqou S, Thompson A, Di AE et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J. Am. Coll. Cardiol. 55(19), 2160–2167 (2010).
   Google Scholar
• Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273(1), 6–30 (2013).
   Google Scholar
• Gurdasani D, Sjouke B, Tsimikas S et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler. Thromb. Vasc. Biol. 32(12), 3058–3065 (2012).
   Google Scholar
• Tselmin S, Julius U, Muller G, Fischer S, Bornstein SR. Cardiovascular events in patients with increased lipoprotein (a) – retrospective data analysis in an outpatient department of lipid disorders. Atheroscler. Suppl. 10(5), 79–84 (2009).
   Google Scholar
• Ezhov MV, Safarova MC, Afanas’eva OI, Il’ina LN, Liakishev AA, Pokrovskii SN. [High level of lipoprotein (a) as a predictor of poor long-term prognosis after coronary artery bypass surgery]. Kardiologiia 51(1), 18–22 (2011).
   Google Scholar
• Qin SY, Liu J, Jiang HX, Hu BL, Zhou Y, Olkkonen VM. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies. Atherosclerosis 227(2), 360–366 (2013).
   Google Scholar
• Julius U, Fischer S. Nicotinic acid as a lipidmodifying drug – a review. Atheroscler. Suppl. 14(1), 7–13 (2013).
   Google Scholar
• HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34(17), 1279–1291 (2013).
   Google Scholar
• Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat. Clin. Pract. Cardiovasc. Med. 6(3), 229–239 (2009).
   Google Scholar
• Berthold HK, Descamps OS, Gouni-Berthold I. Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity? Eur. J. Clin. Invest. 43(1), 108–112 (2013).
   Google Scholar
• Kassner U, Vogt A, Rosada A et al. Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). Atheroscler. Suppl. 10(5), 85–88 (2009).
   Google Scholar
• Stefanutti C, Vivenzio A, Di GS, Mazzarella B, Ferraro PM, Abbolito S. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs usual care. Transfus. Apher. Sci. 42(1), 21–26 (2010).
   Google Scholar
• Leebmann J, Roseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease: prospective observational multicenter study. Circulation doi:10.1161/CIRCULATIONAHA.113.002432 (2013) (Epub ahead of print).▪▪ Prospectively performed and confirmed the high effectiveness of lipoprotein apheresis on the incidence of cardiovascular events in patients with isolated elevation of lipoprotein(a).
   Google Scholar
• von Dryander M, Fischer S, Passauer J, Muller G, Bornstein SR, Julius U. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler. Suppl. 14(1), 39–44 (2013).
   Google Scholar
• Mellwig KP, Pulawski E, Horstkotte D, van Buuren F. Lipid apheresis: oxidative stress, rheology, and vasodilatation. Clin. Res. Cardiol. Suppl. 7(Suppl. 1), 45–49 (2012).
   Google Scholar
• Cuchel M, Meagher EA, du Toit TH et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, Phase 3 study. Lancet 381(9860), 40–46 (2013).
   Google Scholar
• Parhofer KG. How will new medications affect the lipoprotein apheresis situation in Germany? Atheroscler. Suppl. 14(1), 71–72 (2013).
   Google Scholar
• Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr. Atheroscler. Rep. 15(3), 310 (2013).
   Google Scholar
• Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 228(1), 18–28 (2013).
   Google Scholar
• Schuff-Werner P, Fenger S, Kohlschein P. Role of lipid apheresis in changing times. Clin. Res. Cardiol. Suppl. 7(Suppl. 1), 7–14 (2012).
   Google Scholar
• Heigl F, Hettich R, Lotz N et al. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany’s largest apheresis center). Atheroscler. Suppl. 10(5), 137–141 (2009).
   Google Scholar
• Heigl F, Hettich R, Eder B, Arendt R. Lipoprotein apheresis standard for apheresis competence centers – an updated synthesis and amendment to pre-existing standards. Atheroscler. Suppl. 14(1), 57–65 (2013).
   Google Scholar
• Tselmin S, Schmitz G, Julius U, Bornstein SR, Barthel A, Graessler J. Acute effects of lipid apheresis on human serum lipidome. Atheroscler. Suppl. 10(5), 27–33 (2009).
   Google Scholar
• Graessler J, Kopprasch S, Passauer J et al. Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile. Atheroscler. Suppl. 14(1), 151–155 (2013).
   Google Scholar